Elanco Animal Health Inc logo

Elanco Animal Health Inc

ELAN
Last price US$24.89
Market cap US$12.4b
12M price change 69.47%
Loading the 12-month Mave Thesis and 1-month news signal

Dashboard Funda..tals Prediction Screener Map

Elanco Animal Health Inc Overview

Industry: Drug Manufacturers Specialty & Generic

Sector: Healthcare

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. The company was founded in 1954 and is headquartered in Greenfield, Indiana. Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto Read More

Mavefund brings filings, fundamentals, valuation, price history and news for Elanco Animal Health Inc into one research view. The sections below show what strengthens or weakens the research case.

Score

Reported Results

What the company reported, with filing details kept small.

Filed May 06, 2026

Quarterly result summary

Revenue was $1,371M (reported); EPS was $0.4 (reported).

Revenue $1,371M reported
EPS $0.4 reported
Net income $57M reported
Adjusted EBITDA $334M reported

What changed

  • Revenue reported to $1,371M; EPS reported to $0.4.

Guidance / outlook

The company anticipates a tailwind to revenue of approximately $60 million from the favorable impact of foreign exchange rates compared to prior year.

Earnings release Open filing

Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

Other recent earnings materials

Prediction-grade evidence

Recent News

Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.

Earnings Per Share

Score 3.00/5
Elanco Animal Health Inc boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
In Drug Manufacturers Specialty & Generic industry , Zoetis Inc , Amphastar P , Prestige Consumer Healthcare are companies with high ratings.

Return on Equity

Score 3.17/5
Elanco Animal Health Inc stands out with a superior score in the Return on Equity (ROE) section, surpassing the sector median value and showcasing its strong performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
Elanco Anima... ELAN US$12.4b
Zoetis Inc ZTS US$31.9b
IQVIA Holdin... IQV US$34.8b
Agilent Tech... A US$37.9b

Net Margin

Score 2.24/5
Elanco Animal Health Inc olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
Elanco Anima... ELAN US$12.4b
Zoetis Inc ZTS US$31.9b
IQVIA Holdin... IQV US$34.8b
Agilent Tech... A US$37.9b

Share Buyback

In Drug Manufacturers Specialty & Generic industry , Zoetis Inc , Amphastar P , Prestige Consumer Healthcare are companies with high ratings.

Leverage

Score 1.86/5
Elanco Animal Health Inc registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc have achieved high scores.
Elanco Anima... ELAN US$12.4b
Zoetis Inc ZTS US$31.9b
IQVIA Holdin... IQV US$34.8b
Agilent Tech... A US$37.9b

Financial Statements

Company-reported SEC EDGAR facts organized into the three core statements.

Verified SEC statements load when this section enters view.

Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

Financial Ratio

Yearly Quarterly

Financial
Profitability
Growth
Cash Flow
Financial Health
Efficiency Ratios

Elanco Animal Health Inc logo

Elanco Animal Health Inc

US$24.89

US$0.42

-98.3% vs price

US$12.4b

-3.69%

69.47%